» Articles » PMID: 23444052

Impact of Pre-treatment Prostate Tissue Androgen Content on the Prediction of Castration-resistant Prostate Cancer Development in Patients Treated with Primary Androgen Deprivation Therapy

Overview
Journal Andrology
Date 2013 Feb 28
PMID 23444052
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Great advances in tissue androgen analysis using liquid chromatography-tandem mass spectrometry (LC-MS/MS) have made it possible to evaluate the tissue androgen content from a single needle prostate biopsy specimen. In this study, we investigated if pre-treatment androgen content in prostate biopsy specimens could predict their response to primary androgen deprivation therapy (ADT) and future castration-resistant prostate cancer (CRPC). One-hundred and sixty-five prostate cancer patients who received primary ADT were enrolled. They had received multiple core prostate needle biopsy at diagnosis, and an additional one needle biopsy specimen was obtained for tissue androgen determination using LC-MS/MS. The patients' prostate specific antigen (PSA) values were periodically followed during the treatment and patients were determined to have CRPC when their PSA value increased continuously to 25% above the nadir and a 2.0 ng/mL increase. A significant correlation was found between PSA value decline velocity (PSA half-time) after ADT and pre-ADT tissue androgen content. Twenty-three patients were determined to have CRPC. These CRPC patients had a significantly high concentration of tissue T (p < 0.01) and low concentration of tissue 5α-dihydrotestosterone (DHT) (p < 0.01), resulting in a higher tissue T/DHT ratio (p < 0.001). A multivariate Cox proportional hazard model revealed the pre-ADT tissue T/DHT ratio and Gleason score as independent predictors for CRPC development. By using the two statistically significant variables, the relative risk of CRPC development could be calculated. The results of this study suggest that the evaluation of prostate androgen content in a single needle biopsy specimen may be useful to predict future CRPC development after primary ADT. Further studies are required for the clinical application of T/DHT ratio evaluation.

Citing Articles

Salvage Androgen Deprivation Therapy as Potential Treatment for Recurrence after Robot-Assisted Radical Prostatectomy.

Kano H, Kadono Y, Naito R, Makino T, Iwamoto H, Yaegashi H Cancers (Basel). 2024; 16(7).

PMID: 38610982 PMC: 11011007. DOI: 10.3390/cancers16071304.


Early upregulation of AR and steroidogenesis enzyme expression after 3 months of androgen-deprivation therapy.

Hamid A, Kusuma Putra H, Sari N, Diana P, Serani Sesari S, Novita E BMC Urol. 2020; 20(1):71.

PMID: 32560654 PMC: 7304221. DOI: 10.1186/s12894-020-00627-0.


Steroid hormone synthetic pathways in prostate cancer.

Mostaghel E Transl Androl Urol. 2014; 2(3):212-227.

PMID: 25379460 PMC: 4219921. DOI: 10.3978/j.issn.2223-4683.2013.09.16.


High testosterone levels in prostate tissue obtained by needle biopsy correlate with poor-prognosis factors in prostate cancer patients.

Miyoshi Y, Uemura H, Umemoto S, Sakamaki K, Morita S, Suzuki K BMC Cancer. 2014; 14:717.

PMID: 25256077 PMC: 4190297. DOI: 10.1186/1471-2407-14-717.


HEXIM1 plays a critical role in the inhibition of the androgen receptor by anti-androgens.

Yeh I, Song K, Wittmann B, Bai X, Danielpour D, Montano M Biochem J. 2014; 462(2):315-27.

PMID: 24844355 PMC: 5705236. DOI: 10.1042/BJ20140174.